PL1636185T3 - Nowe formy krystaliczne peryndoprylu erbuminy - Google Patents

Nowe formy krystaliczne peryndoprylu erbuminy

Info

Publication number: PL1636185T3
Authority: PL; Poland
Prior art keywords: crystalline form; stirring; water; perindopril erbumine; tert
Prior art date: 2003-06-24

Application number

PL04737029T

Other languages

English (en)

Inventor

Christoph Strässler

Vit Lellek

Roger Fässler

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-24

Filing date

2004-06-18

Publication date

2012-12-31

2004-06-18 Application filed by Servier Lab filed Critical Servier Lab

2012-12-31 Publication of PL1636185T3 publication Critical patent/PL1636185T3/pl

Links

229960003929 perindopril erbumine Drugs 0.000 title abstract 3
IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 title abstract 3
238000003756 stirring Methods 0.000 abstract 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 5
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 abstract 4
238000002425 crystallisation Methods 0.000 abstract 2
230000008025 crystallization Effects 0.000 abstract 2
238000010899 nucleation Methods 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
238000010533 azeotropic distillation Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Indole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

PL04737029T 2003-06-24 2004-06-18 Nowe formy krystaliczne peryndoprylu erbuminy PL1636185T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CH11092003		2003-06-24
EP04737029A EP1636185B1 (de)	2003-06-24	2004-06-18	Neue kristalline formen von perindopril erbumine
PCT/CH2004/000374 WO2004113293A1 (de)	2003-06-24	2004-06-18	Neue kristalline formen von perindopril erbumine

Publications (1)

Publication Number	Publication Date
PL1636185T3 true PL1636185T3 (pl)	2012-12-31

Family

ID=33520350

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04737029T PL1636185T3 (pl)	2003-06-24	2004-06-18	Nowe formy krystaliczne peryndoprylu erbuminy

Country Status (21)

Country	Link
US (2)	US7705046B2 (pl)
EP (1)	EP1636185B1 (pl)
JP (1)	JP2007507418A (pl)
KR (1)	KR20060035636A (pl)
CN (2)	CN100395235C (pl)
AT (1)	ATE540924T1 (pl)
AU (1)	AU2004249345B8 (pl)
BR (1)	BRPI0411966A (pl)
CA (1)	CA2530550C (pl)
CY (1)	CY1112597T1 (pl)
DK (1)	DK1636185T3 (pl)
EA (1)	EA008603B1 (pl)
ES (1)	ES2382171T3 (pl)
MX (1)	MXPA05013811A (pl)
NO (1)	NO333128B1 (pl)
NZ (1)	NZ544160A (pl)
PL (1)	PL1636185T3 (pl)
PT (1)	PT1636185E (pl)
SI (1)	SI1636185T1 (pl)
WO (1)	WO2004113293A1 (pl)
ZA (1)	ZA200600655B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG125975A1 (en) *	2005-03-11	2006-10-30	Servier Lab	New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
SG125976A1 (en) *	2005-03-11	2006-10-30	Servier Lab	New gama crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
WO2007017894A2 (en) *	2005-05-05	2007-02-15	Arch Pharmalabs Limited	PREPARATION OF NOVEL CRYSTALLINE η(ETA) FORM OF PERINDOPRIL ERBUMINE
WO2007017893A2 (en) *	2005-05-05	2007-02-15	Arch Pharmalabs Limited	Preparation of novel crystalline form of perindopril erbumine monohydrate
CA2618516A1 (en) *	2005-08-12	2007-02-22	Sandoz Ag	New crystalline form of perindopril erbumine
JP4923050B2 (ja) *	2005-08-12	2012-04-25	レツク・フアーマシユーテイカルズ・デー・デー	ペリンドプリルエルブミンの調製方法
EP1815857A1 (en)	2006-02-02	2007-08-08	LEK Pharmaceuticals D.D.	A pharmaceutical composition comprising perindopril
WO2007092758A2 (en) *	2006-02-03	2007-08-16	Dr. Reddy's Laboratories Ltd.	Crystalline forms of perindopril erbumine
EA200600630A1 (ru) *	2006-04-20	2007-02-27	ИСМАГИЛОВ, Искандар Халиуллович	ζ-ЗЕТА ФОРМА ПЕРИНДОПРИЛ ЭРБУМИНА
WO2008050185A2 (en) *	2006-10-26	2008-05-02	Glenmark Pharmaceuticals Limited	Novel polymorphs of perindopril erbumine
EP2137148A1 (en) *	2007-03-22	2009-12-30	Aarti Healthcare Limited	Process for the preparation of perindopril erbumine salt and novel polymorph (s) thereof
SI22543A (sl)	2007-06-27	2008-12-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Nove soli perindoprila
PT105315B (pt)	2010-09-29	2013-01-16	Inst Superior Tecnico	Uma nova forma cristalina hidratada de erbumina de perindopril, métodos para a sua preparação e sua utilização em preparações farmacêuticas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2503155A2 (fr)	1980-10-02	1982-10-08	Science Union & Cie	Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
US4508729A (en)	1979-12-07	1985-04-02	Adir	Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
FR2620709B1 (fr)	1987-09-17	1990-09-07	Adir	Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese
US5519146A (en) *	1993-01-08	1996-05-21	Kanegafuchi Kagaku Kogyo Kabushiki Kaisha	Process for crystallizing N2 - ((S) -1-ethoxycarbonyl-3-phenylpropyl)-N6 -trifluoroacetyl-L-lysyl-L-proline
FR2807431B1 (fr)	2000-04-06	2002-07-19	Adir	Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
FR2811320B1 (fr) *	2000-07-06	2002-08-23	Adir	Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811319B1 (fr) *	2000-07-06	2002-08-23	Adir	Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811318B1 (fr)	2000-07-06	2002-08-23	Adir	Nouvelle forme cristalline gamma du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2827860B1 (fr)	2001-07-24	2004-12-10	Servier Lab	Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril
GB2395195A (en) *	2002-11-18	2004-05-19	Cipla Ltd	Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors
JP2009519972A (ja) *	2005-12-15	2009-05-21	アキュスフィア，インコーポレイテッド	粒子ベースの経肺投与または経鼻投与用製薬の製造方法

2004
- 2004-06-18 AT AT04737029T patent/ATE540924T1/de active
- 2004-06-18 DK DK04737029.1T patent/DK1636185T3/da active
- 2004-06-18 MX MXPA05013811A patent/MXPA05013811A/es active IP Right Grant
- 2004-06-18 US US10/560,464 patent/US7705046B2/en not_active Expired - Fee Related
- 2004-06-18 EA EA200501859A patent/EA008603B1/ru not_active IP Right Cessation
- 2004-06-18 CN CNB2004800178672A patent/CN100395235C/zh not_active Expired - Fee Related
- 2004-06-18 PT PT04737029T patent/PT1636185E/pt unknown
- 2004-06-18 CN CNA2008100912488A patent/CN101333181A/zh active Pending
- 2004-06-18 BR BRPI0411966-5A patent/BRPI0411966A/pt not_active Application Discontinuation
- 2004-06-18 CA CA2530550A patent/CA2530550C/en not_active Expired - Fee Related
- 2004-06-18 NZ NZ544160A patent/NZ544160A/en not_active IP Right Cessation
- 2004-06-18 JP JP2006515624A patent/JP2007507418A/ja active Pending
- 2004-06-18 AU AU2004249345A patent/AU2004249345B8/en not_active Ceased
- 2004-06-18 WO PCT/CH2004/000374 patent/WO2004113293A1/de not_active Ceased
- 2004-06-18 EP EP04737029A patent/EP1636185B1/de not_active Expired - Lifetime
- 2004-06-18 PL PL04737029T patent/PL1636185T3/pl unknown
- 2004-06-18 KR KR1020057024852A patent/KR20060035636A/ko not_active Ceased
- 2004-06-18 ES ES04737029T patent/ES2382171T3/es not_active Expired - Lifetime
- 2004-06-18 SI SI200431851T patent/SI1636185T1/sl unknown
2006
- 2006-01-18 NO NO20060256A patent/NO333128B1/no not_active IP Right Cessation
- 2006-01-23 ZA ZA200600655A patent/ZA200600655B/en unknown
2010
- 2010-03-09 US US12/720,250 patent/US7981921B2/en not_active Expired - Fee Related
2012
- 2012-04-04 CY CY20121100334T patent/CY1112597T1/el unknown

Also Published As

Publication number	Publication date
SI1636185T1 (sl)	2012-06-29
JP2007507418A (ja)	2007-03-29
CN1812971A (zh)	2006-08-02
CY1112597T1 (el)	2016-02-10
WO2004113293A1 (de)	2004-12-29
HK1093984A1 (zh)	2007-03-16
AU2004249345A1 (en)	2004-12-29
US7705046B2 (en)	2010-04-27
US20100160404A1 (en)	2010-06-24
BRPI0411966A (pt)	2006-08-29
CN101333181A (zh)	2008-12-31
EP1636185B1 (de)	2012-01-11
NO20060256L (no)	2006-01-18
NO333128B1 (no)	2013-03-11
CN100395235C (zh)	2008-06-18
EP1636185A1 (de)	2006-03-22
CA2530550C (en)	2017-04-04
EA008603B1 (ru)	2007-06-29
DK1636185T3 (da)	2012-05-07
AU2004249345B2 (en)	2009-02-26
US20070135512A1 (en)	2007-06-14
NZ544160A (en)	2008-07-31
MXPA05013811A (es)	2006-06-27
ES2382171T3 (es)	2012-06-06
AU2004249345B8 (en)	2009-06-25
ATE540924T1 (de)	2012-01-15
ZA200600655B (en)	2007-05-30
PT1636185E (pt)	2012-04-16
KR20060035636A (ko)	2006-04-26
US7981921B2 (en)	2011-07-19
CA2530550A1 (en)	2004-12-08
EA200501859A1 (ru)	2006-06-30

Publication	Publication Date	Title
CY1112597T1 (el)	2016-02-10	Νεες κρυσταλλικες μορφες της ερβουμινικης περινδοπριλης
Cavallito et al.	1945	The antibacterial principle of Allium sativum. III. Its precursor and “essential oil of garlic”
AU2002359164A1 (en)	2003-07-09	Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
WO2008035686A1 (en)	2008-03-27	Agent for improving insulin resistance
CN1284063A (zh)	2001-02-14	新化合物
FI91156B (fi)	1994-02-15	Menetelmä uusien terapeuttisesti käyttökelpoisten neplanosiinijohdannaisten valmistamiseksi
JPH02777A (ja)	1990-01-05	新規化合物、その製法及びそれを含む医薬組成物
Goldstein et al.	1974	Isosteres of natural phosphates. 2. Synthesis of the monosodium salt of 4-hydroxy-3-oxobutyl-l-phosphonic acid an isostere of dihydroxyacetone phosphate
JP6178520B2 (ja)	2017-08-09	新規な抗ｈｐｖ医薬製剤の用途
WO2008039087A3 (en)	2008-08-14	Indoline derivatives and uses thereof
JP2022537518A (ja)	2022-08-26	脳神経または心臓保護剤としてのアミノチオール系化合物の使用
NO173822B (no)	1993-11-01	Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse (4-amino-2,6-dimetylfenylsulfonyl)nitrometan og farmasoeytisk akseptable salter derav
KR20000026053A (ko)	2000-05-06	류코트리엔 생성 저해활성을 가지는 신이 추출물 및 신이로부터분리한 리그난 화합물
WO1998056759A3 (de)	1999-09-16	Neue pentaerythritderivate, deren herstellung und verwendung sowie intermediate zur synthese derselben
FR2533566A1 (fr)	1984-03-30	Imino- et amino-acides acyloxycetone-substitues a action therapeutique
ATE38470T1 (de)	1988-11-15	Pharmazeutisches produkt zur behandlung der hypertonie und thromboembolischer krankheiten.
GEP20043408B (en)	2004-06-10	Process For Preparing 6-(4-Chlorophenyl)- 2,2-Dimethyl-7-Phenyl-2,3-Dihydro-1H-Pyrrolizin-5-YL-Acetic Acid, Pharmaceutical Composition Containing Them and Use Thereof for Treatment of Disorders of the Rheumatic Type
KR20010086473A (ko)	2001-09-12	류코트리엔 생성 저해활성을 가지는 정유 성분
CA1322531C (en)	1993-09-28	Phenolic thioethers as inhibitors of 5-lipoxygenase
KR100355497B1 (ko)	2002-12-28	류코트리엔생성저해활성을가지는정유성분
CN101775378A (zh)	2010-07-14	一种酶制剂的制备方法
Von Korff et al.	1958	A DIFFERENCE IN BOVINE AND HUMAN FIBRINO-PEPTIDES WITH RESPECT TO THE OCCURRENCE OF TYROSINE-O-SULFATE
CN101307080A (zh)	2008-11-19	具有镇静活性的5-(4-β-D-吡喃阿洛糖苷-苯基)-3-芳基-4,5-二氢吡唑-1-硫代酰胺类化合物的制备
EP0261891A3 (en)	1990-09-05	Pharmaceutical compositions containing etiochiolandione
JPS62132878A (ja)	1987-06-16	新生理活性物質モナコリンｍ及びその製造法